Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Akb-9778
1. 1008510-37-9
2. Akb-9778
3. Razuprotafib [inn]
4. Razuprotafib [usan]
5. 0wax4ut396
6. Razuprotafib (usan)
7. [4-[(2s)-2-[[(2s)-2-(methoxycarbonylamino)-3-phenylpropanoyl]amino]-2-(2-thiophen-2-yl-1,3-thiazol-4-yl)ethyl]phenyl]sulfamic Acid
8. Carbamic Acid, N-((1s)-2-oxo-1-(phenylmethyl)-2-(((1s)-2-(4-(sulfoamino)phenyl)-1-(2-(2-thienyl)-4-thiazolyl)ethyl)amino)ethyl)-, C-methyl Ester
9. N-(4-{(2s)-2-{(2s)-2-[(methoxycarbonyl)amino]-3-phenylpropanamido}-2-[2-(thiophen-2-yl)-1,3-thiazol-4-yl]ethyl}phenyl)sulfamic Acid
10. Razuprotafib [usan:inn]
11. Unii-0wax4ut396
12. Razuprotafib [who-dd]
13. Schembl679459
14. Chembl3931971
15. Gtpl11336
16. Akb9778
17. Bdbm359124
18. Us10220048, Compound Aa34
19. Who 10271
20. Compound Aa34 [us10220048]
21. At18581
22. Hy-109041
23. Cs-0031483
24. D11540
25. N-(4-((2s)-2-((2s)-2-((methoxycarbonyl)amino)- 3-phenylpropanamido)-2-(2-(thiophen-2-yl)-1,3-thiazol4-yl)ethyl)phenyl)sulfamic Acid
Molecular Weight | 586.7 g/mol |
---|---|
Molecular Formula | C26H26N4O6S3 |
XLogP3 | 3.7 |
Hydrogen Bond Donor Count | 4 |
Hydrogen Bond Acceptor Count | 10 |
Rotatable Bond Count | 12 |
Exact Mass | 586.10144808 g/mol |
Monoisotopic Mass | 586.10144808 g/mol |
Topological Polar Surface Area | 212 Ų |
Heavy Atom Count | 39 |
Formal Charge | 0 |
Complexity | 906 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 2 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Razuprotafib inhibits [VE-PTP](https://go.drugbank.com/bio_entities/BE0003769) (a negative regulator of Tie2 in diseased blood vessels) by binding and inhibiting the intracellular catalytic domain of VE-PTP that inactivates Tie2. This in turn allows razuprotafib to restore Tie2 activation to allow for enhancement of endothelial function and stabilization of blood vessels. Razuprotafib is being investigated against diabetic vascular complications and acute respiratory distress syndrome (ARDS) in COVID-19.
ABOUT THIS PAGE
A Razuprotafib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Razuprotafib, including repackagers and relabelers. The FDA regulates Razuprotafib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Razuprotafib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Razuprotafib supplier is an individual or a company that provides Razuprotafib active pharmaceutical ingredient (API) or Razuprotafib finished formulations upon request. The Razuprotafib suppliers may include Razuprotafib API manufacturers, exporters, distributors and traders.
Razuprotafib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Razuprotafib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Razuprotafib GMP manufacturer or Razuprotafib GMP API supplier for your needs.
A Razuprotafib CoA (Certificate of Analysis) is a formal document that attests to Razuprotafib's compliance with Razuprotafib specifications and serves as a tool for batch-level quality control.
Razuprotafib CoA mostly includes findings from lab analyses of a specific batch. For each Razuprotafib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Razuprotafib may be tested according to a variety of international standards, such as European Pharmacopoeia (Razuprotafib EP), Razuprotafib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Razuprotafib USP).
LOOKING FOR A SUPPLIER?